exhibit 10. 46 * * * text omitted and filed separately with the securities and exchange commission. confidential treatment requested under 17 c. f. r. sections 200. 80 ( b ) ( 4 ) and 240. 24b - 2. execution version settlement and termination agreement by and between amylin pharmaceuticals, inc. and eli lilly and company november 7, 2011 table of contents page article 1 definitions 2 section 1. 1 definitions 2 section 1. 2 other defined terms 22 article 2 termination of collaboration agreement and related agreements 24 section 2. 1 termination of collaboration agreement 24 section 2. 2 related agreements and related third party agreements 24 section 2. 3 reversion of license rights in the collaboration agreement and related agreements 28 article 3 settlement and release 28 section 3. 1 dismissals 28 section 3. 2 amylin release 28 section 3. 3 lilly release 29 section 3. 4 covenants not to sue 30 section 3. 5 right to defend 31 section 3. 6 excluded claims 31 article 4 consideration 32 section 4. 1 upfront payment 32 section 4. 2 milestone payment and other payments 32 section 4. 3 revenue sharing obligation 32 section 4. 4 payments of total revenue sharing obligation 33 section 4. 5 payments upon bydureon approval failure 34 section 4. 6 termination of revenue sharing obligations 34 section 4. 7 records 37 section 4. 8 reports 37 section 4. 9 lilly audit rights 37 section 4. 10 reconciliation under collaboration agreement 38 section 4. 11 reconciliation audit right 38 section 4. 12 payment ; late payment charges 39 section 4. 13 amylin audit rights 40 article 5 intellectual property ; assignment and licenses 41 section 5. 1 ownership 41 section 5. 2 assignment 42 section 5. 3 licenses 42 page article 1 definitions section 1. 1 section 1. 2 article 2 termination of collaboration agreement and related agreements section 2. 1 section 2. 2 section 2. 3 article 3 settlement and release section 3. 1 section 3. 2 section 3. 3 section 3. 4 section 3. 5 section 3. 6 article 4 consideration section 4. 1 section 4. 2 section 4. 3 section 4. 4 section 4. 5 section 4. 6 section 4. 7 section 4. 8 section 4. 9 section 4. 10 section 4. 11 section 4. 12 section 4. 13 article 5 intellectual property ; assignment and licenses section 5. 1 section 5. 2 section 5. 3 i article 6 us transition 45 section 6. 1 termination of lilly commercialization in the united states